A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. by Tisdale, M. J. & Brennan, R. A.
B a 8 8 The Macmillan Press Ltd., 1988
A comparison of long-chain triglycerides and medium-chain
triglycerides on weight loss and tumour size in a cachexia model
M.J. Tisdale & R.A. Brennan
CRC Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK.
Summary A comparison has been made between the ability of long-chain triglycerides (LCT) and medium-
chain triglycerides (MCT) to prevent weight loss induced by the cachexia-inducing colon adenocarcinoma
(MAC16) and to reduce tumour size. There was no difference in calorie consumption or nitrogen intake
between the various groups. When compared with a normal control high carbohydrate, low fat diet, animals
fed MCT showed a reduced weight loss and a marked reduction in tumour size. In contrast neither weight
loss nor tumour size differed significantly from the controls in animals fed the LCT diet. An elevated plasma
level of 3-hydroxybuturate was found only in the animals fed the MCT diets. Administration of LCT caused
an increase in the plasma level of FFA, which was not observed in the MCT group. These results suggest that
diets containing MCT would provide the best ketogenic regime to reverse the weight loss in cancer cachexia
with a concomitant reduction in tumour size.
Weight loss is a common feature of many neoplastic diseases
(De Wys, 1986) and appears to be independent of the
tumour burden and often precedes clinical diagnosis. The
end result of the continuing decline in nutritional status is
the clinical syndrome of cancer cachexia. Patients with
weight loss have a poorer response to chemotherapy and a
shorter survival time than those without weight loss (De Wys
et al., 1980).
We have utilized the MAC16 adenocarcinoma of the
mouse colon as an experimental model of human cachexia,
where weight loss arises from the metabolic effects of the
tumour on the host (Bibby et al., 1987). Animals bearing the
MAC16 tumour show weight loss at small tumour burdens
(less than 1% of the host weight) and without a reduction in
either food or water intake. Weight loss is characterized by a
progressive loss of both body fat and muscle dry weight,
which increases in direct proportion to the tumour burden
(Beck & Tisdale, 1987). Although there is extensive mobiliza-
tion of body fat reserves ketosis does not occur (Bibby et al.,
1987). Ketonuria has also been shown not to occur in cancer
patients (Conyers et al., 1979). Since ketone bodies are
believed to play an important role in the regulation of lean
body mass during starvation we and others (Tisdale, 1982;
Magee et al., 1979; Williamson & Matthaei, 1981) have sug-
gested that a high fat/low carbohydrate ketogenic diet should
also preserve lean body mass during cancer cachexia, and
would not be expected to be utilized by a poorly vascular-
ized tumour, which would depend primarily on glucose as an
energy source. In addition 3-hydroxybutyrate has recently
been shown to inhibit the lipolytic and proteolytic factors
produced by the MAC16 tumour and which may be respon-
sible for the cachexia (Beck & Tisdale, 1987). Such an
approach has been vindicated since mice bearing the MAC16
tumour fed a diet in which up to 80% of the energy was
supplied as medium-chain triglycerides (MCT) show a reduc-
tion in both the extent of weight loss and tumour weight
(Tisdale et al., 1987). A ketogenic diet containing 70% MCT
and supplemented with D-3-hydroxybutyrate administered to
weight losing cachectic cancer patients also caused a gain in
body weight (Fearon et al., 1988).
In our initial investigations we utilized medium-chain
triglycerides (MCT) to induce ketosis, since they are trans-
ported directly via the hepatic portal vein circulation to the
liver, where they are rapidly oxidized to 2 carbon units by #-
oxidation and yield high levels of ketone bodies (Cotter et
al., 1987). In contrast long-chain triglycerides (LCT) are
absorbed via the intestinal lymphatic ducts and transported
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in chylomicrons through the thoracic duct to reach the
systemic circulation and are not so efffective at inducing
ketosis. This study compares the effect of LCT and MCT
with or without D(-)3-hydroxybutyrate supplementation on
experimentally induced cachexia in animals bearing the
MAC16 tumour. Any differences can be attributed to the
elevation of ketone bodies rather than just the replacement
of the carbohydrate component of the diet by fat.
Materials and methods
Chemicals were obtained from Sigma Chemical Co., Poole,
Dorset, UK, unless otherwise stated. A Wako NEFA C kit
for FFA determination in plasma was obtained from Alpha
Laboratories Ltd., Hampshire, UK. Pure strain NMRI mice
were purchased from Banting and Kingman, Hull, UK. Rat
and mouse breeding diet, soya, sodium caseinate, rodent 006
premix and dicalcium phosphate were all purchased from
Pilsbury's Ltd., Birmingham, UK. The MCT emulsion was
obtained from Scientific Hospital Supplies Ltd., Liverpool,
UK, and contained 1.1% C6, 81.1% C8, 15.7% C10 and
2.1% C12 fatty acids. The LCT was formulated into a
chocolate compound by Cadbury Schweppes Ltd., Birm-
ingham, UK., since no commercial LCT emulsion was
available to provide the required level of dietary fat. The
fatty acid composition was 24.2% C16, 36.9% C18, 33.7%
C18.1, 3.0% C18.2, 1.0% C20.
Animals
Fragments of the MAC16 tumour from animals with proven
weight loss were implanted into the flank of male NMRI
mice by means of a trochar. All animals were given free
access to rat and mouse breeding diet for 18 days after
transplantation at which time the tumours were palpable.
They were then randomly divided into 5 groups of 6 animals
each and weighed. The experiment was repeated twice. Body
weights and food and water intake were measured daily
during the course of the study, which was continued until 27
days after transplantation. The starting body weight was
chosen as the day .after the diets were initiated.
Diets
The standard food was rat and mouse breeding diet, which
contained 50% carbohydrate and supplied 11.5% of the
energy as fat. An isocaloric, isonitrogenous diet supplying
68% of the calories as MCT was calculated based on the
composition of the normal diet and was formulated as a
paste to minimize food scatter as previously described (Tis-
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dale et al., 1987). The LCT was formulated as a chocolate
also to minimize wastage and supplied 69% of the calories
as fat derived from cocoa buter and was isonitrogenous with
the other diets as calculated by the relevant compositions
supplied by Cadbury Schweppes. D-(-)3-hydroxybutyrate
was presented as the sodium salt in the drinking water at a
concentration of 30 ymolml-1. Both food and water intake
were monitored daily and scattered food was collected in a
tray under the cages and subtracted to give the actual food
intake. The average daily water consumption per mouse for
the groups containing D-(-)3-hydroxybutyrate was 4.1 ml.
Body weights were measured daily at the same time of day.
At the end of the study blood samples were removed from
animals under anaesthesia by cardiac puncture and were
collected in heparinized syringes. All blood samples were
taken between 9.00 and 11.00 a.m. Blood glucose and FFA
were determined immediately and the remaining samples
were deproteinized for determination of acetoacetate, 3-
hydroxybutyrate and lactate. Results were analysed statisti-
cally using the analysis of variance or F-ratio.
Metabolic assays
Blood glucose Whole blood (0.2ml) was used and glucose
was determined using the o-toluidine reagent kit (Sigma).
Acetoacetate and 3-hydroxybutyrate levels were measured
by the method of Mellanby and Williamson (1974) and
Williamson and Mellanby (1974) respectively. Lactate
levels were determined by the method of Gutmann and
Wahlefield (1974). FFA levels were measured with a Wako
NEFAC kit.
Results
The effect of dietary modification on weight loss and tumour
weight in mice bearing the MAC16 tumour is shown in
Figure 1 and Table I. The average daily food consumption
by all dietary groups was not significantly different and
water consumption also did not vary. The groups containing
D-(-)3-hydroxybutyrate in the drinking water consumed
-120ymol day-1. Animals fed the normal diet lost 20%
of their body weight during the course of the study and this
weight loss was only significantly reduced in the animals fed
68% MCT plus 3-hydroxybutyrate (P<0.05). Tumour
weights appeared to be reduced in all animals fed the high
fat diets, although this only reached significance in the
groups fed 68% MCT with or without 3-hydroxybutyrate,
where the tumour weight was only
- 50% of that found in
the group consuming normal laboratory pellets (P<0.05).
Animals fed the LCT diet had higher levels of circulatory
FFA than those fed MCT and normal diets, and this became
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Figure 1 Effect of dietary modification on weight loss in male
NMRI mice bearing the MAC16 adenocarcinoma. Dietary
groups: A - normal diet; B - 68% MCT; C - 68% MCT+3-
hydroxybutyrate; D - 69% LCT. E - 69% LCT+3-
hydroxybutyrate. Animals were fed the different diets for the
periods indicated in Materials and methods.
statistically significant in the group fed 69% LCT+3-
hydroxybutyrate (P<0.05). Acetoacetate levels were signifi-
cantly elevated from animals fed the normal diet only in the
groups fed MCT. In contrast 3-hydroxybutyrate levels were
elevated over the control in all groups except those fed the
69% LCT diet alone. The group fed 68% MCT+3-
hydroxybutyrate had significantly higher plasma levels of
3-hydroxybutyrate than the group fed LCT+3-
hydroxybutyrate. Blood glucose levels were not significantly
altered in any of the dietary groups. Plasma lactate levels
were significantly reduced in both the 68% MCT +3-
hydroxybutyrate and in the 69% LCT groups.
Discussion
We have previously shown that both weight loss and tumour
weight are reduced in animals bearing the MAC16 tumour
when they are fed a ketogenic diet (Tisdale et al., 1987).
Ketone bodies might be expected to preserve lean body mass
during periods of weight loss and to be poor metabolic
substrates for the tumour (Tisdale & Brennan, 1983; Rofe et
al., 1986). Additional rationalization for the use of a ketoge-
nic diet for the reversal of the weight loss in cancer cachexia
has come from recent studies showing inhibition of lipolytic
and proteolytic factors produced by the MAC16 tumour by
sodium D-(-)3-hydroxybutyrate (Beck & Tisdale, 1987). Such
Table I Effect of dietary modification on weight loss, tumour weight and plasma metabolite levels in NMRI mice bearing the MAC16
adenocarcinomaa
Dietry group
Parameter
Initial weight (g)
Final weight (g)
(- tumour weight)
Weight loss (g)
Food intake
(Kcal mouse- 1 day-)
Tumour weight (g)
FFA (mM)
Acetoacetate (mM)
3-Hydroxybutyrate (mM)
Glucose (mg 100ml-1)
Lactate (mM)
Normal
28.5 +0.5
23.6 +1.9
4.9 + 1.8
15.1 +0.8
0.45 +0.14
0.39 +0.11
0.06 +0.01
0.064+0.002
95 + 13
13.3 + 1.9
68% MCT+
68% MCT 3-hydroxybutyrate
29.3 +0.9
26.8 + 1.2
2.5 +1.4
14.2 +1.0
0.21 +0.09b
0.49 +0.11
0.165 +0.05b
0.13 +0.015c
117+20
11.7 +0.8
28.3 +0.4
27.0 + 1.2
1.3 + 1.4b
14.0 +0.7
0.19+0.05b
0.50 +0.05
0.18 +0.12
0.28 +0.03c
81+7
9.5 +0.8b
69% LCT+
69% LCT 3-hydroxybutyrate
28.6 +0.5
25.7 + 1.2
3.0 +1.6
16.4 + 1.4
0.29 +0.12
0.66 +0.27
0.05 +0.01
0.056+0.009
107+ 10
8.8 +l.lb
28.7 +1.1
25.5 +2.1
3.2 +1.4
15.8 +0.8
0.26 +0.11
0.74 +0.14b
0.06 +0.01
0.108+0.022b
100+9
12.1 +1.3
aResults are means +s.e.m.; bp<0.05 from tumour-bearing group fed a normal diet; CP<0.005 from tumour-bearing group fed a normal
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tumour elaborated catabolic factors are found in the circula-
tion of animals bearing the MAC16 tumour and are thought
to be responsible for the cachexia.
To investigate other dietary lipids as anticachectic agents
we have compared the ability of MCT and LCT to reduce
weight loss and tumour size in the MAC16 cachexia model.
In our initial studies we utilized MCT emulsion as a caloric
source since the yield of ketone bodies was expected to be
higher than for LTC (Cotter et al., 1987). Although ketosis
is absent in cancer cachexia, tumour-bearing animals
respond to starvation with an enhanced ketonaemia and
marked ketonuria, when compared with non tumour-bearing
controls (Rofe et al., 1986). This shows that there is no
functional impairment of the ketogenic capacity of the liver
in the tumour-bearing state, and this has been confirmed by
the increased plasma levels of acetoacetate and 3-
hydroxybutyrate previously observed in weight-losing,
tumour-bearing animals fed high levels of MCT (Tisdale et
al., 1987). Therefore an anticachectic diet should give the
highest level of ketone bodies achievable for a given level of
dietary fat.
Diets containing MCT produced a higher plasma level of
both acetoacetate and 3-hydroxybutyrate than a comparable
LCT diet. The plasma level of 3-hydroxybutyrate has pre-
viously been shown to be elevated after MCT ingestion, but
not after LCT ingestion (Seaton et al., 1986; Cotter et al.,
1987). Diets containing MCT also protected against weight
loss produced by the MAC16 tumour and reduced tumour
weight to a greater extent than those containing LCT, even
when the latter diets were supplemented with 3-
hydroxybutyrate. Some tumours, such as Ehrlich ascites
tumour cells, have been shown to metabolize exogenous long
chain fatty acid (16 to 18 carbon atoms) rapidly relative to
the limited ability to metabolize those of shorter chain length
(Spector & Steinberg, 1967). This could pose a potential
problem of an enhanced tumour growth in some cases if
LCT are used as a source of dietary lipid. In the present
study, however, there was no increase in tumour growth in
the animals fed the LCT diets.
Another potential problem in feeding patients a high fat
diet is the ability of dietary lipids, in particularly unsaturated
fat, to promote tumour development and metastasis, particu-
larly with mammary tumours (Sylvester et al., 1986; Abra-
ham & Hillyard, 1983; Katz & Boyulan, 1987). However,
using the N-nitrosourea rat mammary tumour model, Cohen
and Thompson (1987) have shown that a MCT-containing
diet failed to promote tumour development, when compared
with a high fat corn oil group, indicating that tumour
promotion by dietary fat is more a function of the type than
the amount ingested.
Since weight loss produced by the MAC16 tumour is
proportional to tumour weight (Bibby et al., 1987; Beck &
Tisdale, 1987) it is possible that the prevention of weight loss
by the MCT diets is due to a reduction in tumour weight.
However, we have previously shown (Tisdale et al., 1987)
that a high MCT diet reduces weight loss to a greater extent
than might be anticipated from the reduction in tumour size.
Moreover, 3-hydroxybutyrate has no effect on the growth of
the MAC16 in vitro at concentrations up to 6mm, suggesting
no direct antitumour effect.
Although the MAC16 tumour has a large necrotic centre
(Bibby et al., 1987) there is no evidence for the involvement
of tumour necrosis factor in the production of the cachectic
state (Mahony et al., 1988). Tumours from animals fed the
MCT diets are possibly less necrotic than those fed a normal
diet, but no less necrotic than a tumour of comparable size
from animals fed a normal diet. The contribution of a
reduction in necrosis to the observed reduction in tumour
weight is currently being investigated.
The only potential disadvantage in using MCT is that they
have been shown to increase the basal metabolic rate more
than LCT (Seaton et al., 1986). This could potentially pose
problems in cachectic patients with an already elevated basal
metabolic rate (Theologides, 1979), although none have been
observed in our initial clinical study (Fearon et al., 1988).
Otherwise it is suggested that a high MCT diet supplemented
with 3-hydroxybutyrate would be most suitable for clinical
studies in cachectic cancer patients.
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